You are looking at PPS outside of market cap, potential, etc. a very rookie mistake or basher tactic. Look at ADHD its at 19 and has no product coming next year. ANAC will beat Valeant to market, with a drug that though less effective requires no surgical debris prior to use. We have a partnership with Bill Gates foundation to develop a specific drug, Now the U.S. Govt, as well. There are 7 other drugs in the works not including what Bill Gates and The U.S. Govt are asking them to develop.
BioTech stocks trade on potential, not actual value. Its like the P/E on other stocks, and if you can't see the value in ANAC you should short it. I wish you the best (worst) in that.